11/18/2024

Insulin Aspart Injection

Reason for the Shortage

- Novo Nordisk has all presentations available. The company did not provide availability information on Relion products.

Available Products

- Fiasp subcutaneous injection, Novo Nordisk, 100 units/mL, 10 mL multiple dose vial, 1 count, NDC 00169-3201-11
- Fiasp Flextouch subcutaneous injection, Novo Nordisk, 100 units/mL, 3 mL pen, 5 count, NDC 00169-3204-15
- Fiasp Penfill subcutaneous injection, Novo Nordisk, 100 units/mL, 3 mL pen, 5 count, NDC 00169-3205-15
- Insulin Aspart Flexpen subcutaneous injection, Novo Nordisk, 100 units/mL, 3 mL pen, 5 count, NDC 73070-0103-15
- Insulin Aspart Penfill subcutaneous injection, Novo Nordisk, 100 units/mL, 3 mL pen, 5 count, NDC 73070-0102-15
- Novolog subcutaneous injection, Novo Nordisk, 100 units/mL, 10 mL multiple dose vial, 1 count, NDC 00169-7501-11
- Novolog Flexpen subcutaneous injection, Novo Nordisk, 100 units/mL, 3 mL pen, 5 count, NDC 00169-6339-10
- Novolog Penfill subcutaneous injection, Novo Nordisk, 100 units/mL, 3 mL pen, 5 count, NDC 00169-3303-12
- Insulin Aspart subcutaneous injection, Novo Nordisk, 100 units/mL, 10 mL multiple dose vial, 1 count, NDC 73070-0100-11

Updated

Updated November 18, 2024 by Leslie Jensen, PharmD, Drug Information Specialist. Created November 10, 2023 by Leslie Jensen, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.